US 11,655,506 B2
Therapeutic target for musculoskeletal inflammation
Anna Plaas, Chicago, IL (US); Vincent Wang, Naperville, IL (US); John Sandy, Chicago, IL (US); Rebecca Bell, New York, NY (US); Jorge Galante, Sanibel, FL (US); and Katie J. Trella, Chicago, IL (US)
Assigned to Rush University Medical Center, Chicago, IL (US); and The Board of Trustees of the University of Illinois, Urbana, IL (US)
Appl. No. 15/111,395
Filed by Rush University Medical Center, Chicago, IL (US); and The Board of Trustees of the University of Illinois, Urbana, IL (US)
PCT Filed Jan. 14, 2015, PCT No. PCT/US2015/011380
§ 371(c)(1), (2) Date Jul. 13, 2016,
PCT Pub. No. WO2015/108958, PCT Pub. Date Jul. 23, 2015.
Claims priority of provisional application 61/927,070, filed on Jan. 14, 2014.
Prior Publication US 2016/0333410 A1, Nov. 17, 2016
Int. Cl. C12Q 1/6883 (2018.01); G01N 33/68 (2006.01); A61K 38/18 (2006.01); A61K 38/43 (2006.01)
CPC C12Q 1/6883 (2013.01) [A61K 38/1841 (2013.01); A61K 38/43 (2013.01); G01N 33/6887 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/10 (2013.01); G01N 2800/52 (2013.01)] 5 Claims
 
1. A method of treating a musculoskeletal disorder in a subject; the method comprising administering an enzymatic therapy to reduce an amount of an aggrecan-hyaluronan matrix of the subject from a treatment site in the subject to treat the musculoskeletal disorder and measuring a level of the aggrecan-hyaluronan matrix before administering the enzymatic therapy and after administering the therapy to determine a reduction in the amount of the aggrecan-hyaluronan matrix; and wherein the enzymatic therapy comprises chondrolytic biologics.